Skip to main content
letter
. 2020 Jun 19;5:100. doi: 10.1038/s41392-020-0211-1

Fig. 1.

Fig. 1

Levels of CCGFs increased in COVID-19 patients. a Levels of CCGFs that were increased in COVID-19 patients but not correlated to disease severity. b Levels of CCGFs that were increased in COVID-19 patients and positively correlated to COVID-19 disease severity. c Levels of CCGFs that were increased in COVID-19 patients and negatively correlated to COVID-19 disease severity. Dynamic levels of the indicated CCGFs in plasma samples of mild (n = 10), severe (n = 7), and fatal (n = 6) COVID-19 patients at the indicated days after diagnosis as well as healthy individuals (n = 4) were measured by Bio-plex. Data shown are averages plus SD of the CCGF levels in mild, severe, and fatal COVID-19 patients, and averages of the CCGF levels in healthy individuals (dotted line). *p < 0.05; **p < 0.01 (Turkey’s test as described in Supplementary Information)